Cell therapy for diabetic neuropathy using adult stem or progenitor cells

Ji Woong Han, Min Young Sin, Youngsup Yoon

Research output: Contribution to journalReview article

18 Citations (Scopus)

Abstract

Diabetic neuropathy (DN) is the most common and disabling complication of diabetes that may lead to foot ulcers and limb amputations.Despite widespread awareness of DN, the only effective treatments are glucose control andpain management. A growing body of evidence suggests that DN is characterized by reduction of vascularity in peripheral nerves and deficiency in neurotrophic and angiogenic factors. Previous studies have tried to introduce neurotrophic or angiogenic factors in the form of protein or gene for therapy, but the effect was not significant.Recent studies have shown that bone marrow (BM)-derived stem or progenitor cells have favorable effects on the repair of cardiovascular diseases. Since these BM-derived stem or progenitor cells contain various angiogenic and neurotrophicfactors, these cells have been attempted for treatingexperimental DN, and turned out to be effective forreversing various manifestations of experimental DN. These evidences suggest that cell therapy, affecting both vascular and neural components, can represent a novel therapeutic option for treatment of clinical DN.

Original languageEnglish
Pages (from-to)91-105
Number of pages15
JournalDiabetes and Metabolism Journal
Volume37
Issue number2
DOIs
Publication statusPublished - 2013 Apr 1

Fingerprint

Adult Stem Cells
Diabetic Neuropathies
Cell- and Tissue-Based Therapy
Stem Cells
Angiogenesis Inducing Agents
Nerve Growth Factors
Bone Marrow
Foot Ulcer
Diabetes Complications
Peripheral Nerves
Amputation
Genetic Therapy
Blood Vessels
Cardiovascular Diseases
Therapeutics
Extremities
Glucose
Proteins

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism

Cite this

@article{6c95015c7ba643918b8cd0a6372509dd,
title = "Cell therapy for diabetic neuropathy using adult stem or progenitor cells",
abstract = "Diabetic neuropathy (DN) is the most common and disabling complication of diabetes that may lead to foot ulcers and limb amputations.Despite widespread awareness of DN, the only effective treatments are glucose control andpain management. A growing body of evidence suggests that DN is characterized by reduction of vascularity in peripheral nerves and deficiency in neurotrophic and angiogenic factors. Previous studies have tried to introduce neurotrophic or angiogenic factors in the form of protein or gene for therapy, but the effect was not significant.Recent studies have shown that bone marrow (BM)-derived stem or progenitor cells have favorable effects on the repair of cardiovascular diseases. Since these BM-derived stem or progenitor cells contain various angiogenic and neurotrophicfactors, these cells have been attempted for treatingexperimental DN, and turned out to be effective forreversing various manifestations of experimental DN. These evidences suggest that cell therapy, affecting both vascular and neural components, can represent a novel therapeutic option for treatment of clinical DN.",
author = "Han, {Ji Woong} and Sin, {Min Young} and Youngsup Yoon",
year = "2013",
month = "4",
day = "1",
doi = "10.4093/dmj.2013.37.2.91",
language = "English",
volume = "37",
pages = "91--105",
journal = "Diabetes and Metabolism Journal",
issn = "2233-6079",
publisher = "Korean Diabetes Association",
number = "2",

}

Cell therapy for diabetic neuropathy using adult stem or progenitor cells. / Han, Ji Woong; Sin, Min Young; Yoon, Youngsup.

In: Diabetes and Metabolism Journal, Vol. 37, No. 2, 01.04.2013, p. 91-105.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Cell therapy for diabetic neuropathy using adult stem or progenitor cells

AU - Han, Ji Woong

AU - Sin, Min Young

AU - Yoon, Youngsup

PY - 2013/4/1

Y1 - 2013/4/1

N2 - Diabetic neuropathy (DN) is the most common and disabling complication of diabetes that may lead to foot ulcers and limb amputations.Despite widespread awareness of DN, the only effective treatments are glucose control andpain management. A growing body of evidence suggests that DN is characterized by reduction of vascularity in peripheral nerves and deficiency in neurotrophic and angiogenic factors. Previous studies have tried to introduce neurotrophic or angiogenic factors in the form of protein or gene for therapy, but the effect was not significant.Recent studies have shown that bone marrow (BM)-derived stem or progenitor cells have favorable effects on the repair of cardiovascular diseases. Since these BM-derived stem or progenitor cells contain various angiogenic and neurotrophicfactors, these cells have been attempted for treatingexperimental DN, and turned out to be effective forreversing various manifestations of experimental DN. These evidences suggest that cell therapy, affecting both vascular and neural components, can represent a novel therapeutic option for treatment of clinical DN.

AB - Diabetic neuropathy (DN) is the most common and disabling complication of diabetes that may lead to foot ulcers and limb amputations.Despite widespread awareness of DN, the only effective treatments are glucose control andpain management. A growing body of evidence suggests that DN is characterized by reduction of vascularity in peripheral nerves and deficiency in neurotrophic and angiogenic factors. Previous studies have tried to introduce neurotrophic or angiogenic factors in the form of protein or gene for therapy, but the effect was not significant.Recent studies have shown that bone marrow (BM)-derived stem or progenitor cells have favorable effects on the repair of cardiovascular diseases. Since these BM-derived stem or progenitor cells contain various angiogenic and neurotrophicfactors, these cells have been attempted for treatingexperimental DN, and turned out to be effective forreversing various manifestations of experimental DN. These evidences suggest that cell therapy, affecting both vascular and neural components, can represent a novel therapeutic option for treatment of clinical DN.

UR - http://www.scopus.com/inward/record.url?scp=84877825231&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877825231&partnerID=8YFLogxK

U2 - 10.4093/dmj.2013.37.2.91

DO - 10.4093/dmj.2013.37.2.91

M3 - Review article

C2 - 23641349

AN - SCOPUS:84877825231

VL - 37

SP - 91

EP - 105

JO - Diabetes and Metabolism Journal

JF - Diabetes and Metabolism Journal

SN - 2233-6079

IS - 2

ER -